A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab

• Автори: Madelyn Espinosa-Cotton (Автор), Elana J. Fertig (Автор), Laura P. Stabile (Автор), Autumn Gaither-Davis (Автор), Julie E. Bauman (Автор), Sandra Schmitz (Автор), Katherine N. Gibson-Corley (Автор), Yinwen Cheng (Автор), Isaac J. Jensen (Автор), Vladimir P. Badovinac (Автор), Douglas Laux (Автор), Andrean L. Simons (Автор)
• Формат: Книга
• Опубліковано: BMC, 2019-07-01T00:00:00Z.
• Предмети: article
• Онлайн доступ: Connect to this object online.

Abstract Background The epidermal growth factor receptor (EGFR) monoclonal IgG1 antibody cetuximab is approved for first-line treatment of recurrent and metastatic (R/M) HNSCC as a part of the standard of care EXTREME regimen (platinum/5-fluorouracil/cetuximab). This regimen has relatively high resp...